Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on therapy for heart failure.

Robert DiBianco1

  • 1Department of Cardiology, Washington Adventist Hospital, Takoma Park, Maryland 20912, USA. DrDibianco@aol.com

The American Journal of Medicine
|October 18, 2003
PubMed
Summary

Angiotensin II receptor blockers offer additional benefits for heart failure patients, improving outcomes and tolerability compared to ACE inhibitors. Spironolactone also shows additive benefits, with guidelines recommending these agents for selected heart failure cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

"Acute Red Eye in Contact Lens Users: Clinical Pearls for Frontline Clinicians".

The American journal of medicine·2026
Same journal

Effect of routinely tailoring anti-hypertensive therapy to hemodynamic profile in primary care.

The American journal of medicine·2026
Same journal

Impedance Cardiography in Hypertension: Precision Medicine or Gizmo Idolatry?

The American journal of medicine·2026
Same journal

Mineralocorticoid Antagonists for Post-MI HFpEF: Plausible Biology Meets Low Residual Risk?

The American journal of medicine·2026
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Angiotensin-converting enzyme (ACE) inhibitors have proven effective in reducing heart failure morbidity and mortality.
  • Further research into the renin-angiotensin-aldosterone system (RAAS) inhibitors is ongoing.
  • ACE inhibitors are first-line treatments for heart failure and left ventricular dysfunction.

Purpose of the Study:

  • To investigate the role and benefits of newer RAAS inhibitors, specifically angiotensin II receptor blockers (ARBs).
  • To compare the efficacy and tolerability of ARBs against existing treatments.
  • To evaluate the additive benefits of aldosterone antagonists like spironolactone.

Main Methods:

  • Review of clinical trial evidence on ARBs in heart failure.
  • Analysis of ARBs' impact on morbidity and mortality endpoints.
  • Assessment of spironolactone's additive effects when used with ACE inhibitors.

Main Results:

  • ARBs may provide additional benefits by more completely blocking angiotensin II effects.
  • ARBs demonstrate an improved adverse-effect profile, suitable for ACE inhibitor-intolerant patients.
  • Clinical trials confirm ARBs' beneficial effects on heart failure morbidity and mortality.
  • Spironolactone shows additive benefits in patients already on ACE inhibitors.

Conclusions:

  • ARBs represent a valuable therapeutic option for heart failure management.
  • ARBs offer an alternative for patients who cannot tolerate ACE inhibitors.
  • Current heart failure guidelines recommend ARBs and spironolactone for selected patients.

Related Experiment Videos